NIFTY200 Alpha 30

Pursuant to Regulation 30 of the SEBI Listing Regulations, TVS Motor Company has informed that TVS Motor Company at its meeting today, i.e., May 18, 2026, has approved the execution, delivery and performance of the share purchase agreement (SPA) to be executed between the Company and the Jana Holdings (Seller) in relation to the proposed purchase of 51,60,903 equity shares constituting 4.90% of the paid-up share capital of Jana Small Finance Bank (Target), as on 18 May 2026. The details with respect to the above acquisition, as required under the SEBI Listing Regulations read with the SEBI Master Circular dated January 30, 2026, bearing reference number SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 (Master Circular), are set forth in Annexure A below. Further, the intimation is also given in compliance with Reg 30(4) read with Clause A(1)(ii)(c) of Part A of Schedule III of the SEBI Listing Regulations. The meeting of the Investment Committee of the Board of Directors commenced at 10:45 AM (IST) and concluded at 12:05 PM (IST). A press release in this regard is enclosed.

The above information is a part of company’s filings submitted to BSE.

The Federal Bank has informed that, as approved by the Nomination, Remuneration, Ethics and Compensation Committee, the following allotments have been made after payment of money by the allottees: 1. Allotment of 3,250 Equity Shares with face value of Rs. 2/- each of the Bank to the Option Grantees upon exercise of stock options under ESOS 2010 Scheme on May 17, 2026. 2. Allotment of 2,12,167 Equity Shares with face value of Rs. 2/- each of the Bank to the Option Grantees upon exercise of stock options under ESOS 2017 Scheme on May 17, 2026.

The above information is a part of company’s filings submitted to BSE.

One 97 Communications has informed that it enclosed a press release titled as ‘Paytm Launches Pocket Money, Bringing Paytm UPI Payments to Teenagers Without a Bank Account’. This disclosure will also be hosted on the Company's website: https://ir.paytm.com/.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. Glenmark’s Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.